See all results for ""
Sameer Sah

Sameer Sah

, Mumbai

Partner | Corporate and Commercial, Private Equity, Pharmaceuticals


  • B.Sc., LL.B., (Hons.), National Law University, Jodhpur (2007)

Sameer Sah is Partner in the Corporate and Commercial Practice Group in the Mumbai office.  Sameer specialises in the areas of strategic M&A, joint ventures, collaborations, foreign investments, private equity, and regulatory approvals for investing in India.  He also advises clients on regulatory and other issues pertaining to the pharmaceutical, healthcare, retail and franchising sectors.

Professional Affiliations

  • Bar Council of Maharashtra & Goa
  • International Bar Association
  • Association Internationale des Jeunes Avocats
  • All India Federation of Tax Practitioners
  • Chamber of Tax Consultants
  • American Bar Association (Health Law and International Law Section)
  • American Health Lawyers Association

Representative Matters

Sameer Sah has represented and advised the following clients

Reliance Jio

Advised on acquisition of the mobile business assets (including the spectrum, mobile towers and optical fibre network) of Reliance Communications.

Ingenico Group

Advised as an Indian Legal Counsel on acquisition of 100% of TechProcess Payment Services Limited.

GlaxoSmithKline Plc (GSK)

Advised on its three-part global transaction with Novartis AG (Novartis), pursuant to which GSK is forming a consumer health joint venture with Novartis, while at the same time buying Novartis’ vaccines business and divesting its cancer drugs portfolio to Novartis.

Mitsui & Co. (Asia Pacific) Pte. Ltd

Advised on acquisition of a minority stake in Keimed Private Limited.

Otsuka Pharmaceutical Factory, Inc. and Mitsui & Co., Ltd

Advised on their joint venture with Claris Lifesciences Limited.

Advent International Corporation

Advised on their affiliates’ investment of US$105 million in Quality Care India Limited.

Eris Lifesciences Private Limited

Advised on the stake purchase by Chrys Capital.

Lyndsay Goldberg

Advised on (i) divestment of their investment in Weener Plastik AG, and (ii) on the investment in Weener Plastik AG.

Meiji-Seika Pharma

Advised on acquisition of Medreich Limited.


iconErgo Update

15 Sep '20
Classification for Newly Notified Medical Devices

iconExternal Links

22 May '20
Impact of Covid 19 on M&A

iconExternal Links

02 Apr '20
Impact of COVID-19 on pharma supply chains


30 Mar '20
Software as a medical device


13 Mar '20
Deal-Making in the COVID-19 times


11 Mar '20
How will the new medical-device rules impact financial investors?

News and Events

Sameer Sah has featured in the following news and webinars

Similar profiles